Valse Avec Bachir – Le Film

Main Menu

  • Israel
  • Haifa
  • West Bank
  • Tel Aviv
  • Financial Affairs

Valse Avec Bachir – Le Film

Header Banner

Valse Avec Bachir – Le Film

  • Israel
  • Haifa
  • West Bank
  • Tel Aviv
  • Financial Affairs
Israel
Home›Israel›Israel-produced COVID-19 vaccine candidate plans booster against Omicron variant – Precision vaccinations

Israel-produced COVID-19 vaccine candidate plans booster against Omicron variant – Precision vaccinations

By Shelly J. Cazares
January 11, 2022
0
0
(Precision vaccinations)

Pennsylvania-based NRx Pharmaceuticals today confirmed new information regarding the experimental BriLife ™ vaccine for COVID-19.

Last week, NRx met with experts from the Israel Institute for Biological Research (IIBR) to review data and research related to the ability of the BriLife vaccine to induce neutralizing antibodies against the Omicron variant.

Based on the preliminary results, NRx is currently designing a Phase 2b / 3 study of the BriLife vaccine as a booster to protect against variants of concern of COVID-19, including the Omicron variant.

Patients in the advanced study will be fully immunized with mRNA vaccines.

NRx said it expects the study to begin in the first quarter of 2021 in Israel and be extended in coordination with health ministries in several countries.

Professor Jonathan Javitt, MD, MPH, President and CEO of NRx Pharmaceuticals, commented in a press release issued on January 11, 2022: “We are working closely with the experts at IIBR to design a study which, we hopefully, increases BriLife’s accelerated path to regulatory approval. “

In addition, the Israeli Ministry of Health recently approved a study on the NanoPass MicronJet ™ intradermal injection system for the BriLife vaccine.

The NanoPass system, invented in Israel, uses a patented micro-needle system to deliver the vaccine into the skin with minimal discomfort.

This approach is particularly promising for the BriLife vaccine because it binds to angiotensin converting ACE2 receptors, which are present in significantly greater amounts in human skin cells than in muscle cells where traditional vaccines are injected.

Additionally, early data with other vaccines suggests that intradermal administration of BriLife may result in a more robust immune response at significantly lower vaccine doses.

In addition, NRx continues its technology transfer and scale-up activities to anticipate commercial scale manufacturing of Brilife by the fourth quarter of 2022.

NRx Pharmaceuticals, located in Radnor, PA, is developing the BriLife ™ Covid vaccine, developed by the Israel Institute for Biological Research, under an exclusive license from the Israeli Ministry of Defense.

Related posts:

  1. Former French envoy to Israel faces backlash following misogynist tweet
  2. Israel reports just 13 new coronavirus cases, lowest number in more than a year
  3. H&M Israel says targeted by Iranian cyberattack
  4. Israel records fewest new coronavirus cases in a year

Recent Posts

  • The debate in Israel continues over Ukrainian refugees
  • Kristian Pitschugin breaks Israeli national record at Israel Association Cup
  • Israel increases its gas production and seeks to supply Europe
  • Palestinian man tries to stab soldier in northern West Bank and is shot by soldiers, IDF says
  • Maccabi held Be’ersheva to a 1-1 draw

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021

Categories

  • Financial Affairs
  • Haifa
  • Israel
  • Tel Aviv
  • West Bank
  • Terms and Conditions
  • Privacy Policy